GeoMx® Protein Assays
Helping Your Research
High-plex Spatial Proteomic Analysis
GeoMx Protein Assays enable quantitative, spatial analysis of 96+ proteins from a single FFPE or Fresh Frozen slide, vastly expanding the number of markers you can profile from a single tissue section compared to traditional immunohistochemical methods. All assays are validated for use in multiplex so you can focus on the biology of interest without wasting time troubleshooting assay performance.
How it Works
The assay relies upon antibodies coupled to photocleavable oligonucleotide tags designed for readout with nCounter® (≤96-plex) or NGS (over 100-plex) platforms. After hybridization of antibodies to slide-mounted tissue sections, the oligonucleotide tags are released from discrete regions of the tissue via UV exposure. Released tags are counted in a standard nCounter assay or sequenced using NGS, and counts are mapped back to tissue location yielding a spatially resolved digital profile of protein abundance.
All GeoMx® Protein Assays undergo extensive validation to ensure high quality GeoMx DSP data. Read more about GeoMx Antibody Validation in this white paper.
Simplify your multiomics studies with the multimodal Spatial Proteogenomics workflow. This workflow enables co-detection of RNA and protein from the same tissue slide on GeoMx® DSP with NGS as the readout method. Harness the sensitivity of both GeoMx RNA Assays and GeoMx Protein Assays to capture a complete picture of your biology starting with transcription to translation with capabilities to measure protein activation and post-translational modifications.
Immuno-Oncology and Immunology
The Immune Cell Profiling Core contains 18 targets for broad cell profiling of human samples (17 targets for mouse) and includes necessary controls for all GeoMx DSP experiments. Up to 6 10-plex modules plus 10 custom targets can be added to select the content most relevant to your human and mouse research.
The Neural Cell Profiling Core contains 20 targets designed for broad cell profiling of human samples (19 targets for mouse) and includes necessary controls for all GeoMx DSP experiments. Up to 6 10-plex modules plus 10 custom targets can be added to select the content most relevant to your human and mouse research.
Designed to profile 10’s-100’s of protein targets simultaneously with spatial resolution using NGS platforms and pipelines. Run the 4-plex GeoMx Protein Core for NGS, which includes necessary controls for GeoMx DSP experiments, with any selection of 10-plex modules.
As part of the overall Custom Protein Workflow, the GeoMx® Protein Barcoding Kit enables researchers to barcode antibodies of interest with a GeoMx DSP barcode in a single day with minimal hands-on time. Once antibodies have been barcoded, researchers can continue with their Custom Protein Workflow for any further appropriate functional testing. When custom antibodies are barcoded with the GeoMx Protein Barcoding kit, the addition of this content to GeoMx Protein Assays enables profiling up to 150 plex in a single experiment.
Sympathetic axonal sprouting induces changes in macrophage populations and protects against pancreatic cancer.
Neuronal nerve processes in the tumor microenvironment were highlighted recently. However, the origin of intra-tumoral nerves remains poorly known, in part because of technical difficulties in tracing nerve fibers via conventional histological preparations.
Immunostimulatory cancer-associated fibroblast subpopulations can predict immunotherapy response in head and neck cancer.
Purpose: Cancer-associated fibroblasts (CAF) have been implicated as potential mediators of checkpoint immunotherapy response. However, the extensive heterogeneity of these cells has precluded rigorous understanding of their immunoregulatory role in the tumor microenvironment.
Spatial profiling reveals association between WNT pathway activation and T-cell exclusion in acquired resistance of synovial sarcoma to NY-ESO-1 transgenic T-cell therapy.
Background: Genetically engineered T-cell immunotherapies for adoptive cell transfer (ACT) have emerged as a promising form of cancer treatment, but many of these patients develop recurrent disease. Furthermore, delineating mechanisms of resistance may be challenging since the analysis of bulk tumor profiling can be complicated by spatial heterogeneity.